Remarks

Applicants have canceled claims 1 to 30, and Applicants have added claims 31 to 43, leaving claims 31 to 43 pending in the present application. Applicants canceled claims 1 to 7, and 11 to 30 in view of the election of claims designated "Group III" by the Examiner. The cancellation of these claims necessitated the deletion of Robyn L. Adams, Anna C. Jelmberg, Stephen R. Jaspers, and Mike R. Stamm as named inventors.

Applicants have focused the claims upon particular aspects of the invention designated Group III in light of commercial considerations, and not for any reason related to patentability. Applicants reserve the right to pursue claims directed to the subject matter of canceled claims in continuation and divisional applications.

Support for claims 31 to 39 can be found at least in original claim 8, and on page 36, last paragraph, of the specification. Support for claims 40 and 41 can be found at least on page 6 (first and fourth paragraphs). Support for claims 42 and 43 can be found at least on page 38, first paragraph, of the specification. No new matter has been added by way of these amendments.

Applicants have attached a marked-up version of the changes made to the application by the present amendment. The attached pages are captioned "Version with Markings to Show Changes Made."

Conclusion

If for any reason the Examiner feels that a telephone conference would expedite prosecution of the application, the Examiner is invited to telephone the undersigned at (206) 442-6681.

Respectfully submitted,
ZymoGenetics, Inc.

Phillip B. C. Jones
Registration No. 38,195

Version with Markings to Show Changes Made

In the Application:

Robyn L. Adams, Anna C. Jelmberg, Stephen R. Jaspers, and Mike R. Stamm were deleted as named inventors.

In the Specification:

The title at line 4 of page 1 has been amended as follows:

Antibodies That Bind Testis-Specific Insulin Homolog Polypeptides

In the Claims:

Claims 1 to 30 have been canceled.

Claims 31 to 43 have been added by amendment. The new claims are:

--31. An antibody, or antibody fragment, that binds to an epitope of a Zins2 polypeptide, wherein the Zins2 polypeptide has an amino acid sequence consisting of SEQ ID NO:13.

32. The antibody of claim 31, wherein the antibody is a monoclonal antibody.

33. The antibody of claim 31, wherein the antibody is a polyclonal antibody.

34. The antibody of claim 31, wherein the antibody is a single-chain antibody.

35. The antibody of claim 31, wherein the antibody is a humanized antibody.

36. The antibody of claim 31, wherein the antibody is a chimeric antibody.

37. The antibody fragment of claim 31, wherein the antibody fragment is an $F(ab')_2$ fragment.

38. The antibody fragment of claim 31, wherein the antibody fragment is an Fab proteolytic fragment.

39. The antibody fragment of claim 31, wherein the antibody fragment is an Fv fragment.

40. The antibody, or antibody fragment, of claim 31, wherein the antibody, or antibody fragment, binds an epitope that resides within acid residues 20 to 54 of SEQ ID NO:13.

41. The antibody, or antibody fragment, of claim 31, wherein the antibody, or antibody fragment, binds an epitope that resides within acid residues 172 to 213 of SEQ ID NO:13.

42. The antibody, or antibody fragment, of claim 31, wherein the antibody, or antibody fragment, further comprises a detectable label.

43. The antibody, or antibody fragment of claim 42, wherein the detectable label is selected from the group consisting of radionuclide, enzyme, fluorescent marker, chemiluminescent marker, and magnetic particle.--